Arylcyclohexylamines

ESO Publishes Peer-Reviewed Paper On Prehospital Ketamine Use At A National Level

Friday, June 11, 2021 - 1:13pm

The study uses data from the ESO Data Collaborative, one of the largest prehospital research databases in the country.

Key Points: 
  • The study uses data from the ESO Data Collaborative, one of the largest prehospital research databases in the country.
  • View the full release here: https://www.businesswire.com/news/home/20210611005060/en/
    The ketamine conversation has reached a national, mainstream audience, said Dr. Brent Myers, Chief Medical Officer for ESO.
  • EMS Ketamine Administrations: Based on data from the ESO Data Collaborative, EMS administered ketamine to 11,291 patients from January 1, 2019-December 31, 2019.
  • ESO (ESO Solutions, Inc.) is dedicated to improving community health and safety through the power of data.

Ketamine One Launches Immersive Virtual Reality R&D Program at MindScape Clinic

Monday, June 7, 2021 - 11:00am

Clinic patients who select IVR-based treatments will receive a tailored therapy plan that includes a determination of their mental state and individual goals.

Key Points: 
  • Clinic patients who select IVR-based treatments will receive a tailored therapy plan that includes a determination of their mental state and individual goals.
  • With over 2,000 treatments administered since inception, MindScape also recently expanded its service offering to provide spa-like therapeutic treatment experiences.
  • Mindscape Ketamine & Infusions Therapy, PLLC is a clinic in Houston, Texas, offering affordable delivery of concierge IV ketamine therapy for treatment-resistant mood disorders, mental health disorders, and chronic pain conditions.
  • Mindscape Ketamine & Infusion Therapy, PLLC is the only IV ketamine clinic in Houston to offer virtual reality-based guided meditation to complement IV ketamine infusions in the treatment of depression, bipolar disorder, anxiety, PTSD, OCD, and other mood disorders.

Ketamine One Signs Definitive Agreement to Acquire Integrated Rehab and Performance Ltd.

Thursday, June 3, 2021 - 11:00am

Pursuant to the terms of the Agreement and subject to the closing of the Transaction, IRPs Founder and Chief Executive Officer (CEO), Steven Inglefield, has agreed to become a director of Ketamine One.

Key Points: 
  • Pursuant to the terms of the Agreement and subject to the closing of the Transaction, IRPs Founder and Chief Executive Officer (CEO), Steven Inglefield, has agreed to become a director of Ketamine One.
  • The IRP team is excited to join Ketamine One and combine resources to grow its clinics across Canada.
  • Currently, Ketamine One has a network of 15 clinics across North America, with plans to further consolidate the highly fragmented industry.
  • As a collective enterprise, Ketamine One is dedicated to helping solve the growing need for safe and accessible mental health therapy.

Ketamine (CAS 6740-88-1) Global Market Research Report 2021 - ResearchAndMarkets.com

Thursday, June 3, 2021 - 10:58am

The "Ketamine (CAS 6740-88-1) Global Market Research Report 2021" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Ketamine (CAS 6740-88-1) Global Market Research Report 2021" report has been added to ResearchAndMarkets.com's offering.
  • This global report is a result of industry experts' diligent work on researching the world market of Ketamine.
  • The fifth chapter deals with Ketamine market trends and forecast, distinguish Ketamine manufacturers and suppliers.
  • The Ketamine global market report key points:

Myconic Capital Becomes Ketamine One

Tuesday, June 1, 2021 - 11:00am

VANCOUVER, British Columbia, June 01, 2021 (GLOBE NEWSWIRE) -- Myconic Capital Corp. (NEO: MEDI) is pleased to announce that effective June 3, 2021 it will change its name to KetamineOne Capital Limited (Ketamine One or the Company) from Myconic Capital Corp. and do business under the Ketamine One brand (the Name Change).

Key Points: 
  • VANCOUVER, British Columbia, June 01, 2021 (GLOBE NEWSWIRE) -- Myconic Capital Corp. (NEO: MEDI) is pleased to announce that effective June 3, 2021 it will change its name to KetamineOne Capital Limited (Ketamine One or the Company) from Myconic Capital Corp. and do business under the Ketamine One brand (the Name Change).
  • Ketamine Ones board of directors has appointed Dr. Mark Kimmins as the Companys Chief Medical Officer.
  • We are excited to reveal the re-brand of the Company to Ketamine One, which more accurately reflects our vision to quickly become a leader in the delivery of breakthrough mental wellbeing treatments, said Adam Deffett, VP of Capital Markets for Ketamine One.
  • KetamineOne Capital Limited (formerly Myconic Capital Corp.) (NEO: MEDI) is a single-purpose company focused becoming a North American leader in mental health.

Braxia Scientific Appoints Dr. David Greenberg to Board of Directors

Monday, May 31, 2021 - 12:01pm

TORONTO, May 31, 2021 /PRNewswire/ - Braxia Scientific Corp. (the "Company"), (CSE: BRAX) (OTC: BRAXF) (FWB: 496), a research driven clinical platform developing and providing innovative ketamine treatments for persons with depression and related disorders, is pleased to announce it has appointed Dr. David Greenberg to its Board of Directors.

Key Points: 
  • TORONTO, May 31, 2021 /PRNewswire/ - Braxia Scientific Corp. (the "Company"), (CSE: BRAX) (OTC: BRAXF) (FWB: 496), a research driven clinical platform developing and providing innovative ketamine treatments for persons with depression and related disorders, is pleased to announce it has appointed Dr. David Greenberg to its Board of Directors.
  • Dr. Greenberg consults for various companies on Sales, Marketing, Communications, and Business Development strategies.
  • Dr. Greenberg developed a national reputation for effectively conveying highly complex issues and concepts in a straightforward and entertaining manner.
  • Braxia Scientific is a research driven medical solutions company that aims to reduce the illness burden of brain-based mental disorders such as major depressive disorder among others.

NeonMind Announces Creation of Medical Clinics Advisory Board to Guide Planning and Operation of Company-Branded Clinics Across Canada

Wednesday, May 26, 2021 - 11:00am

Members of the advisory board will be comprised of experts on provincial and local health care access and advocacy, ketamine treatment and psychotherapy protocols, and clinical operations, strategy, and growth.

Key Points: 
  • Members of the advisory board will be comprised of experts on provincial and local health care access and advocacy, ketamine treatment and psychotherapy protocols, and clinical operations, strategy, and growth.
  • To view an enhanced version of this image, please visit:
    "The formation of our Medical Clinic Advisory Board is a critical next step in the creation of our clinics and treatment models.
  • Currently, ketamine and esketamine may legally be prescribed and administered in Canadian medical clinics, however there is a need for these clinics and treatments to be tailored to community and local health needs.
  • NeonMind established a medical services division with the goal of launching NeonMind-branded specialty mental health clinics in Canada that incorporate evidence-backed innovative treatments to address a variety of mental health needs.

/R E P E A T -- Braxia Scientific Introduces the Braxia Institute, Turning Research to Clinical Action; Over 200 Physicians and Health Care Providers to Attend Braxia's Symposium on Rapid Acting Anti-Depressants/

Thursday, May 20, 2021 - 10:05pm

"With Braxia Scientific\'s knowledge base, we have a tremendous opportunity to radically improve the quality of care patients receive.

Key Points: 
  • "With Braxia Scientific\'s knowledge base, we have a tremendous opportunity to radically improve the quality of care patients receive.
  • Braxia Scientific will play a vital role in translating and implementing the latest research for psychedelic, ketamine and esketamine therapies for persons with depression and related disorders.
  • Braxia Scientific is primarily focused on (i) owning and operating multidisciplinary clinics providing treatment for mental health disorders and (ii) research activities related to discovering and commercializing novel drugs and delivery methods.
  • These factors should be considered carefully, and readers are cautioned not to place undue reliance on such forward-looking statements.

Accomplished Clinical Researcher Matthew Macaluso Joins as Scientific and Clinical Advisor for PharmaTher’s Ketamine Programs

Thursday, May 20, 2021 - 2:28pm

as a scientific and clinical advisor for PharmaTher\xe2\x80\x99s clinical research programs involving ketamine as a potential treatment for major depressive disorders and amyotrophic lateral sclerosis (\xe2\x80\x9cALS\xe2\x80\x9d or \xe2\x80\x9cLou Gehrig\xe2\x80\x99s Disease\xe2\x80\x9d).\nMatthew Macaluso, D.O.

Key Points: 
  • as a scientific and clinical advisor for PharmaTher\xe2\x80\x99s clinical research programs involving ketamine as a potential treatment for major depressive disorders and amyotrophic lateral sclerosis (\xe2\x80\x9cALS\xe2\x80\x9d or \xe2\x80\x9cLou Gehrig\xe2\x80\x99s Disease\xe2\x80\x9d).\nMatthew Macaluso, D.O.
  • Professor Macaluso is also the Clinical Director of the UAB Depression and Suicide Center.
  • Matt has extensive experience in conducting clinical studies involving depression, including being a principal investigator of clinical studies involving esketamine which led to an FDA approval.
  • He is also a co-inventor for the novel use of ketamine as a potential treatment for ALS.

Update for Patient Access Solutions Opening and Managing New Center in Long Island, N.Y.

Thursday, May 20, 2021 - 2:00pm

In addition to strategic relations efforts, PASO is aggressively moving forward into the exciting new area of Biological Mental health solutions.

Key Points: 
  • In addition to strategic relations efforts, PASO is aggressively moving forward into the exciting new area of Biological Mental health solutions.
  • To add value and experience to our Ketamine Therapy product offering, PASO has engaged in ongoing discussions with one of the country\xe2\x80\x99s leading Ketamine Therapy Clinic Companies.
  • A psychiatrist referral is also required.\nAfter an initial consultation, patients will be set up into a 6-9 session program.
  • This information is qualified in its entirety by cautionary statements and risk factors disclosure contained in certain of Patient Access Solutions Inc. Securities and Exchange Commission filings available at http://www.sec.gov .\n'